LongMike, I agree with your assessment that the short selling began once Phase III clinial trils not met beginning at $1.25/share.
One can check the chart and the dates to easily confirm this.
It actually leaked down to $.80 once the announcement came to delay the announcement on the Phase III clinical trial results. Then catostropically dropped to $.05 and below after announcement.
Significant volume went off at $.80 then down to $0.02 with few stop points ).30 & .09 and .05) on no news and no plan to sell product after announced that Phase I trial did not allow for FDA OTC approval for "statistically significant" allergic symptom reductions.
Very little volume was actually available at all to buy at $0.02 even though the stock was at those levels for a long time.
All who could have gotten shares then should have to average down based on the fact that Pre-Hist does work and can make claims from results in FDA Clinical Trials PHase I, II and III (twice) that allergy sufferers did see allergic sysmptom reductions (even though the second Phase III clinical trial did not show "enough statistical significance" for the FDA to grant OTC approval) based on that study and that level of pollen counts...
However over 10,000 people have used the product the past 7 years in clinical trials and for compassionate use. There is some pent-up demand and branding already, including thru the doctors that ran the trials.
Feb is the month to begin actual sales for revenue of Pre-Histin, my understanding.
Successful sales revenue and the stock price will take care of itself.
